KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer

Kiranmai Gumireddy1, Anping Li, Phyllis A Gimotty

  • 1The Wistar Institute, 3601 Spruce Street, PA 19104, USA.

Nature Cell Biology
|October 6, 2009
PubMed

Insights

Researchers identified KLF17 as a novel breast cancer metastasis suppressor. Lower KLF17 levels promote cancer spread and invasion, suggesting its potential as a biomarker for metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastasis, a key factor in cancer mortality, involves complex genetic regulation.
  • Identifying metastasis suppressors is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To discover novel genes that suppress breast cancer metastasis using a forward genetic screen.
  • To elucidate the mechanism by which KLF17 regulates metastasis and its potential as a biomarker.

Main Methods:

  • Genome-wide RNA interference (RNAi) screen in a mouse breast cancer model.
  • Orthotopic transplantation of engineered cells and selection for metastatic variants.
  • Analysis of KLF17's effect on cell invasion, epithelial-mesenchymal transition (EMT), and Id1 gene expression.
  • Validation in human breast cancer samples.

Main Results:

  • KLF17 was identified as a novel metastasis suppressor gene.
  • KLF17 expression inhibits breast cancer cell metastasis, invasion, and EMT.
  • KLF17 directly suppresses the transcription of Id1, a key metastasis regulator.
  • KLF17 is downregulated in human breast cancers, and KLF17/Id1 expression predicts lymph node metastasis.

Conclusions:

  • KLF17 acts as a critical suppressor of breast cancer metastasis.
  • KLF17's regulatory role in Id1 transcription and its downregulation in human tumors highlight its significance.
  • KLF17 and Id1 expression patterns may serve as valuable biomarkers for predicting breast cancer metastasis.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...